Skip to content
Platform
ePORE® therapy Technology
ePORE® therapy Treats
Benefits of ePORE® therapy
EndoVE®
CUTIS
Gastrointestinal Therapy
Clinicians
Patient Information
Skin Therapy
Clinicians
Patient Information
News
About Mirai
Contact
Menu
Platform
ePORE® therapy Technology
ePORE® therapy Treats
Benefits of ePORE® therapy
EndoVE®
CUTIS
Gastrointestinal Therapy
Clinicians
Patient Information
Skin Therapy
Clinicians
Patient Information
News
About Mirai
Contact
News
Filter by Topic
News
White Papers
Mirai Medical attends the Australasian Melanoma Conference (AMC) 2023
Read More
24.03.2023
Mirai Medical treats the first skin cancer patient in Australia with ePORE
®
therapy
Read More
17.03.2023
The first clinical paper published using electroporation in conjunction with calcium for the treatment of colorectal cancer
Read More
13.02.2023
First live surgery demonstration of Mirai Medical’s ePORE
®
therapy for the treatment of gastrointestinal cancers
Read More
2.11.2022
Mirai Medical appoints Paraic Curtis to the board
Read More
30.06.2022
First patient with oesophageal cancer is treated in Germany using ePORE
®
therapy with EndoVE
®
Read More
16.06.2022
Mirai Medical’s ePORE
®
therapy with EndoVE
®
is launched in Spain
Read More
21.04.2022
Mirai Medical launch EndoVE
®
probe in Leeds
Read More
7.04.2022
Mirai Medical Launches its New Website and has Received a Favourable Ethical Opinion for the PIONEER Patient Registry
Read More
24.05.2021
First Patient Enrolled in VECTOR Trial using ePORE
®
therapy for the Treatment of Inoperable Oesophageal and Gastric Cancer
Read More
10.05.2021